

DISCLOSURE OF RELEVANT RELATIONSHIPS & CONFIDENTIALITY STATEMENTS
For NIA-AA Guidelines Workgroup

Confidential

DISCLOSURE OF RELEVANT RELATIONSHIPS

For each of the categories below, (1) please disclose relationships that cover the last 12 months and for anticipated activities in the coming 12 months as of approximately April 2016. If you have none, please write "none." Relationships apply to you and to spouse or dependent children. (2) For each relationship, please indicate whether it is a "Significant (\geq \$1,000) Financial Interest" Financial interests include but are not limited to salary, consulting and / or speaker fees, honoraria, research support, equity interests (e.g., stocks, stock options, or other ownership interests), and intellectual property rights (e.g., patents, copyrights and royalties from such rights).

1. Research funding (federal, foundation and corporate) relevant to the topic of Alzheimer's disease.

For all of the following studies, I receive compensation as salary greater than \$1,000 over the past 12 months and in the coming 12 months.

U48DP005053 Healthy Brain Research Network Collaborating Center (Karlavish) 09/30/14 – 09/30/19

Centers for Disease Control and Prevention, Penn Prevention Research Center, Special Interest Project

U48DP005053 Developing Messages that Promote Awareness & Action about Cognitive Health (Karlavish/Jordan) 09/30/14 – 09/30/16

Centers for Disease Control and Prevention, Penn Prevention Research Center Special Interest Project

P30-AG-10124 (Trojanowski) 07/01/11 – 06/30/16

National Institute on Aging
Alzheimer's Disease Center-Core B

P30-AG-10124 (Trojanowski) 7/01/11 – 06/30/16

National Institute on Aging
Alzheimer's Disease Center-Core E

1R01AG038440 (Black) 09/15/11 – 05/31/16

National Institute on Aging
Ethical issues in Dementia Research involving Surrogate and Study Partners

UF1AG046150 National Institute on Aging (Reiman/Tariot) 03/01/14-6/30/18
Alzheimer's Prevention Initiative

2U19AG010483 (Aisen/Sperling) 12/31/12 - 11/30/17

National Institute on Aging/Alzheimers Disease Cooperative Study
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (The A4 Trial)

SOKRATES: Study of Knowledge and Reactions to Amyloid Testing (Karlawish)
1/1/14 – 6/30/16
Alzheimer's Association & Alzheimer's Foundation of America

U01 – AG10483 (Mobley/Raffi) 07/01/12 – 06/30/17
National Institute on Aging
Alzheimers Disease Cooperative Study
This is a subcontract with the ADCS to chair its internal ethics committee.

1RF1AG047866 (Karlawish/Green) 8/20/15-7/31/19
National Institute on Aging
Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals

2. Consulting to a for-profit company (paid and unpaid) relevant to the topic of Alzheimer's disease.

None.

3. Ownership of property relevant to the topic of Alzheimer's disease (patents filed or approved, licenses and other property shares) -- for each, please indicate whether you do or do not accept royalties.

Penn holds a license on an integrated neurodegenerative disease database. I receive royalties on it. Over the past 12 months I have received none and in te coming 12 months, value is unknown

4. Equity in companies whose work is relevant to the topic of Alzheimer's disease

None.

5. Employment in companies whose work is relevant to the topic of Alzheimer's disease

None.

I will immediately notify NIA-AA Workgroup leads if a change occurs in any of the above during the tenure of my responsibilities,

Name

Signature

Date